AU2009314629B2 - Methods and compositions related to targeting monoacylglycerol lipase - Google Patents
Methods and compositions related to targeting monoacylglycerol lipase Download PDFInfo
- Publication number
- AU2009314629B2 AU2009314629B2 AU2009314629A AU2009314629A AU2009314629B2 AU 2009314629 B2 AU2009314629 B2 AU 2009314629B2 AU 2009314629 A AU2009314629 A AU 2009314629A AU 2009314629 A AU2009314629 A AU 2009314629A AU 2009314629 B2 AU2009314629 B2 AU 2009314629B2
- Authority
- AU
- Australia
- Prior art keywords
- magl
- cells
- compound
- cancer
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19928608P | 2008-11-14 | 2008-11-14 | |
| US61/199,286 | 2008-11-14 | ||
| PCT/US2009/006045 WO2010056309A2 (en) | 2008-11-14 | 2009-11-10 | Methods and compositions related to targeting monoacylglycerol lipase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009314629A1 AU2009314629A1 (en) | 2010-05-20 |
| AU2009314629B2 true AU2009314629B2 (en) | 2014-09-25 |
Family
ID=42170582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009314629A Ceased AU2009314629B2 (en) | 2008-11-14 | 2009-11-10 | Methods and compositions related to targeting monoacylglycerol lipase |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8772318B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2373315A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5576874B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2009314629B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2743861A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010056309A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| EP2828253A1 (en) | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| MX364895B (es) | 2013-03-13 | 2019-05-10 | Forma Therapeutics Inc | Nuevos compuestos y composiciones para la inhibicion de fasn. |
| US9981972B2 (en) | 2014-05-22 | 2018-05-29 | Abide Therapeutics, Inc. | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets |
| WO2016149401A2 (en) | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| US10450302B2 (en) | 2015-05-11 | 2019-10-22 | Lundbeck La Jolla Research Center, Inc. | Methods of treating inflammation or neuropathic pain |
| MX375424B (es) | 2015-07-31 | 2025-03-06 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl |
| EP3331536A4 (en) * | 2015-08-03 | 2019-03-27 | The Regents of The University of California | COMPOSITIONS AND METHODS OF MODULATING THE ABHD2 ACTIVITY |
| US10336709B2 (en) | 2015-10-02 | 2019-07-02 | Abide Therapeutics, Inc | Lp-PLA2 inhibitors |
| US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
| WO2017222713A1 (en) * | 2016-06-24 | 2017-12-28 | Indiana University Research & Technology Corporation | A gpr119-based signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner |
| CN109996790B (zh) | 2016-09-19 | 2023-05-16 | H.隆德贝克有限公司 | 哌嗪氨基甲酸酯及其制备和使用方法 |
| JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| MX2019008626A (es) | 2017-01-20 | 2019-09-19 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). |
| JP2020506903A (ja) | 2017-01-23 | 2020-03-05 | ファイザー・インク | Magl阻害薬としての複素環式スピロ化合物 |
| PT3595665T (pt) | 2017-03-13 | 2024-11-21 | Lundbeck La Jolla Research Center Inc | Inibidores duplos de magl e faah |
| MY200738A (en) | 2017-05-23 | 2024-01-13 | H Lundbeck As | Pyrazole magl inhibitors |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| WO2019200224A1 (en) * | 2018-04-13 | 2019-10-17 | The Broad Institute, Inc. | Synergistic drug combinations predicted from genomic features and single-agent response profiles |
| MA52635A (fr) | 2018-05-15 | 2021-03-24 | H Lundbeck As | Inhibiteurs de magl |
| CA3106510A1 (en) | 2018-07-19 | 2020-01-23 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
| US11147805B2 (en) | 2019-02-07 | 2021-10-19 | Medipure Pharmaceuticals Inc. | Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product |
| CN109750104A (zh) * | 2019-03-18 | 2019-05-14 | 南通大学附属医院 | Abhd6在非小细胞肺癌诊断、预后、治疗产品中的应用 |
| CA3155260A1 (en) * | 2019-09-26 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods for reducing rewarding effects of morphine without affecting its analgesic effects |
| WO2021214550A1 (en) | 2020-04-21 | 2021-10-28 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| TWI924832B (zh) * | 2021-04-01 | 2026-05-11 | 日商小野藥品工業股份有限公司 | Abhd6拮抗劑 |
| CN113527270B (zh) * | 2021-07-16 | 2024-03-01 | 河南大学 | 一种靶向单酰基甘油脂肪酶的protac分子的医药中间体、制备方法及应用 |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
| JP7852604B2 (ja) * | 2022-09-30 | 2026-04-28 | 小野薬品工業株式会社 | Abhd6アンタゴニストを含有する医薬組成物 |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060089406A1 (en) * | 2002-09-19 | 2006-04-27 | John Nieland | Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases |
| WO2006116773A2 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of California | Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders |
| WO2008024408A2 (en) * | 2006-08-22 | 2008-02-28 | Theraquest Biosciences, Inc. | Pharmaceutical formulations of cannabinoids for application to the skin and method of use |
| FR2915197A1 (fr) * | 2007-04-18 | 2008-10-24 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1817025A2 (en) * | 2004-11-23 | 2007-08-15 | PTC Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| US7989623B2 (en) * | 2007-11-21 | 2011-08-02 | Synthon Bv | Process for making n-(diphenylmethyl)piperazines |
| AU2009330821B2 (en) | 2008-12-24 | 2015-06-11 | Bial - Portela & Ca, S.A. | Pharmaceutical compounds |
-
2009
- 2009-11-10 WO PCT/US2009/006045 patent/WO2010056309A2/en not_active Ceased
- 2009-11-10 JP JP2011536316A patent/JP5576874B2/ja not_active Expired - Fee Related
- 2009-11-10 EP EP09826412A patent/EP2373315A4/en not_active Withdrawn
- 2009-11-10 CA CA2743861A patent/CA2743861A1/en not_active Abandoned
- 2009-11-10 AU AU2009314629A patent/AU2009314629B2/en not_active Ceased
- 2009-11-10 US US12/998,642 patent/US8772318B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060089406A1 (en) * | 2002-09-19 | 2006-04-27 | John Nieland | Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases |
| WO2006116773A2 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of California | Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders |
| WO2008024408A2 (en) * | 2006-08-22 | 2008-02-28 | Theraquest Biosciences, Inc. | Pharmaceutical formulations of cannabinoids for application to the skin and method of use |
| FR2915197A1 (fr) * | 2007-04-18 | 2008-10-24 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
Non-Patent Citations (3)
| Title |
|---|
| CHEMBL576786 JZL184 [retrieved on 5 July 2013] Retrieved from internet published on 5 November 2008 * |
| DINH, T.P., ET AL, "RNA Inferference Suggests a Primary Role for Monoacylglycerol Lipase in the Degradation of the Endocannabinoid 2-Arachidonoylglycerol". Molecular Pharmacology, 2004, vol. 66, no. 5, pages 1260-1264 * |
| VISO, A., ET AL, "The Medicinal Chemistry of Agents Targeting Monoacylglycerol Lipase". Current Topics in Medicinal Chemistry, 2008, vol. 8, no. 3, pages 231-246 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012508737A (ja) | 2012-04-12 |
| EP2373315A2 (en) | 2011-10-12 |
| CA2743861A1 (en) | 2010-05-20 |
| US8772318B2 (en) | 2014-07-08 |
| WO2010056309A2 (en) | 2010-05-20 |
| WO2010056309A3 (en) | 2010-07-01 |
| US20110275650A1 (en) | 2011-11-10 |
| EP2373315A4 (en) | 2012-06-27 |
| JP5576874B2 (ja) | 2014-08-20 |
| AU2009314629A1 (en) | 2010-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8772318B2 (en) | Methods and compositions related to targeting monoacylglycerol lipase | |
| Xiang et al. | LncRNA MEG3 targeting miR-424-5p via MAPK signaling pathway mediates neuronal apoptosis in ischemic stroke | |
| Qu et al. | Patchouli alcohol ameliorates dextran sodium sulfate-induced experimental colitis and suppresses tryptophan catabolism | |
| Mei et al. | FA-97, a new synthetic caffeic acid phenethyl ester derivative, ameliorates DSS-induced colitis against oxidative stress by activating Nrf2/HO-1 pathway | |
| Dominguez et al. | Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers | |
| JP2012508737A5 (cg-RX-API-DMAC10.html) | ||
| US20070196395A1 (en) | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain | |
| Han et al. | Discussion on structure classification and regulation function of histone deacetylase and their inhibitor | |
| US9457042B2 (en) | Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired p53 function | |
| Adlimoghaddam et al. | Nilotinib improves bioenergetic profiling in brain astroglia in the 3xTg mouse model of Alzheimer’s disease | |
| Wang et al. | Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide | |
| Song et al. | Anticancer melatplatin prodrugs: high effect and low toxicity, MT1-ER-target and immune response in vivo | |
| Dinavahi et al. | Development of a novel multi-isoform ALDH inhibitor effective as an antimelanoma agent | |
| Hou et al. | Propofol Suppresses Microglia Inflammation by Targeting TGM2/NF‐κB Signaling | |
| Salamoun et al. | 6-Amino [1, 2, 5] oxadiazolo [3, 4-b] pyrazin-5-ol derivatives as efficacious mitochondrial uncouplers in STAM mouse model of nonalcoholic steatohepatitis | |
| WO2019035866A1 (en) | COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX | |
| Shan et al. | Inhibition of epidermal growth factor receptor attenuates LPS-induced inflammation and acute lung injury in rats | |
| Xu et al. | mGluR5-mediated eCB signaling in the nucleus accumbens controls vulnerability to depressive-like behaviors and pain after chronic social defeat stress | |
| US20190091220A1 (en) | Targeting parp1 for treatment of tsc and cancers | |
| Zhao et al. | Crucial role of serum response factor in renal tubular epithelial cell epithelial-mesenchymal transition in hyperuricemic nephropathy | |
| Zhang et al. | GLI1 inhibitor SRI-38832 attenuates chemotherapeutic resistance by downregulating NBS1 transcription in BRAFV600E colorectal cancer | |
| Yang et al. | Sulforaphane mitigates high‐fat diet‐induced obesity by enhancing mitochondrial biogenesis in skeletal muscle via the HDAC8‐PGC1α Axis | |
| Kim et al. | Phloroglucinol Derivatives Exert Anti‐Inflammatory Effects and Attenuate Cognitive Impairment in LPS‐Induced Mouse Model | |
| CN103381269A (zh) | 检测和调节肿瘤细胞对抗有丝分裂剂的敏感性的方法 | |
| Wang et al. | 3‐(3‐Pyridylmethylidene)‐2‐indolinone Reduces the Severity of Colonic Injury in a Murine Model of Experimental Colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application | ||
| NA | Applications received for extensions of time, section 223 |
Free format text: AN APPLICATION TO EXTEND THE TIME FROM 10 NOV 2013 TO 10 JUN 2014 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED . |
|
| NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 10 JUN 2014 . |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |